Mucinous glycoprotein (MUC-1) vaccine
US9173929B2 · kind B2 · utility
0Cited by
23References
27Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 1, 2005 |
| Grant date | Nov 3, 2015 |
| Priority date | — |
| Expiry date | Jun 14, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55572
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.